Patients with recurrent HCV benefit from triple therapy after liver transplant
Triple therapy was effective in a cohort of liver transplant
recipients with recurrent hepatitis C, although adverse events were
common in a recent study.
In a multicenter cohort study in France, researchers evaluated 37 patients with recurrent hepatitis C genotype 1 who underwent liver transplantation
(LT) and received triple therapy with either boceprevir (n=18) or
telaprevir (n=19) in addition to pegylated interferon and ribavirin, for
a median of 41 weeks. The cohort included 18 patients who were
treatment naive and five who had relapsed and 14 who had been
nonresponsive during prior dual therapy after transplantation. Patients
received calcineurin inhibitor (CNI) therapy with cyclosporine (n=22) or
At 12 weeks of treatment, 89% of boceprevir and 58% of telaprevir recipients experienced complete virological response (P=.06), while end-of-treatment response was observed in 72% of evaluable boceprevir recipients and 40% of telaprevir recipients.
Sustained virological response 12 weeks after treatment completion
occurred in 71% of evaluable boceprevir patients and 20% of evaluable
telaprevir recipients (P=.24).